Company: CRNX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001658247-25-000019
Chunk: 55

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part II, Item 6
Chunk 55
---
ITEM 6. EXHIBITS

EXHIBIT INDEX

ExhibitNumberIncorporated by ReferenceFiledHerewithExhibit DescriptionFormFile No.ExhibitFiling Date3.1Amended and Restated Certificate of Incorporation8-K001-385833.37/20/20183.2Amended and Restated Bylaws8-K001-385833.112/12/20234.1Specimen Stock Certificate Evidencing the Shares of Common StockS-1/A333-2258244.17/9/201831.1Certification of Chief Executive Officer pursuant to Rule 13(a)-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002X31.2Certification of Chief Financial Officer pursuant to Rule 13(a)-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002X32.1*Certification of Chief Executive Officer and Chief Financial Officer pursuant 18. U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002X101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL documentX101.SCHInline XBRL Taxonomy Extension Schema Document.X104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)X

*The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Crinetics Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.

29

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Crinetics Pharmaceuticals, Inc.Date: November 6, 2025By:/s/ R. Scott Struthers, Ph.D.R. Scott Struthers, Ph